This study characterized antihyperglycemic medication use after chronic kidney disease onset among patients with type 2 diabetes to uncover potential unmet needs in clinical practice. Conclusions: ...
When it comes to kidney and cardiovascular outcomes, there is no significant difference between treatment with an SGLT2 inhibitor or GLP-1 receptor agonist in patients with type 2 diabetes, according ...
Hydration is a surprisingly important diabetes health factor, and its even more important if you also have chronic kidney disease (CKD). CKD develops in 10 to 40 percent of people with type 2 diabetes ...
In an observational study, SGLT2i and GLP1-RA appeared to offer the most kidney protection in real-world patients with type 2 diabetes. Patients with type 2 diabetes may have the lowest risk of ...
The new type 2 diabetes treatment algorithm consensus statement from the American Association of Clinical Endocrinologists (AACE), running to 48 pages, has been published online and is available for ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results